6-chloro-7-(5,6-dimethyl-2-(thiazol-2-yl)-1H-benzo[d]imidazol-1-yl)quinazoline-2,4-diamine | 1351617-18-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-chloro-7-(5,6-dimethyl-2-(thiazol-2-yl)-1H-benzo[d]imidazol-1-yl)quinazoline-2,4-diamine
• 英文别名: 6-Chloro-7-[5,6-Dimethyl-2-(1,3-Thiazol-2-Yl)-1h-Benzimidazol-1-Yl]quinazoline-2,4-Diamine；6-chloro-7-[5,6-dimethyl-2-(1,3-thiazol-2-yl)benzimidazol-1-yl]quinazoline-2,4-diamine
• CAS: 1351617-18-9
• 化学式: C₂₀H₁₆ClN₇S
• 分子量: 421.913
• InChiKey: WSVACSSBUCFLCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  137
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4，5-二甲基-1，2-苯二胺 在 氧气 、 potassium carbonate 、 溶剂黄146 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 75.33h， 生成 6-chloro-7-(5,6-dimethyl-2-(thiazol-2-yl)-1H-benzo[d]imidazol-1-yl)quinazoline-2,4-diamine
  参考文献：
  名称：

  Structure-Based Design of New Dihydrofolate Reductase Antibacterial Agents: 7-(Benzimidazol-1-yl)-2,4-diaminoquinazolines

  摘要：

  A new series of dihydrofolate reductase (DHFR) inhibitors, the 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines, were designed and optimized for antibacterial potency and enzyme selectivity. The most potent inhibitors in this series contained a five-membered heterocycle at the 2-position of, the benzimidazole, leading to highly potent and selective compounds that exploit the differences in the size of a binding pocket adjacent to the NADPH cofactor between the bacterial and human DHFR enzymes. Typical of these compounds is 74(2-thiazol-2-yObenzimidazol-1-yl)-2,4 diaminoquinazoline, which is a potent inhibitor of S. aureus DHFR (K-i = 0.002 nM) with 46700-fold selectivity over human DHFR. This compound also has high antibacterial potency on Gram-positive bacteria with an MIC versus wild type S. aureus of 0.0125 mu g/mL and a MIC versus trimethoprim-resistant S. aureus of 0.25 mu g/mL. In vivo efficacy versus a S. aureus septicemia was demonstrated, highlighting the potential of this new series.

  DOI：

  10.1021/jm401204g

文献信息

• DIHYDROFOLATE REDUCTASE INHIBITORS
  申请人：Chen Zhiyong

  公开号：US20120136014A1

  公开（公告）日：2012-05-31

  The present disclosure provides compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R 5 , R 6 and Z are as described herein. The disclosure also provides pharmaceutical compositions thereof; and methods for inhibiting DHFR activity; and methods for treating cell proliferative diseases, autoimmune disease, inflammatory disease or bacterial, fungal or parasitic infection by administering a compound of Formula I.

  本公开提供公式I的化合物：或其药学上可接受的盐，其中R5，R6和Z如本文所述。本公开还提供其制药组合物；以及通过给予公式I的化合物来抑制DHFR活性的方法；以及通过给予公式I的化合物来治疗细胞增殖性疾病，自身免疫性疾病，炎症性疾病或细菌，真菌或寄生虫感染的方法。
• US8835445B2
  申请人：——

  公开号：US8835445B2

  公开（公告）日：2014-09-16